BIRC5 and neuroendocrine neoplasm: Survivin-based vaccines have been explored in multiple clinical settings.14, 15, 16,22,23 SurVaxM, also a survivin peptide vaccine, demonstrated safety and preliminary efficacy in phase 1 trials for glioblastoma16 and neuroendocrine tumours,15 though its immunogenicity was limited to specific HLA haplotypes (HLA-A∗02, -A∗03, -A∗11, or -A∗24).